Organon (OGN) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
The meeting was conducted virtually to enhance inclusivity and shareholder participation, with voting and Q&A capabilities provided online.
All board members, executive officers, and key external representatives, including the independent auditor and inspector of elections, were present.
The agenda included director elections, executive compensation, incentive plan amendments, auditor ratification, and a shareholder proposal.
Board and executive committee updates
Board nominees for re-election were listed, and the board unanimously recommended approval of all management proposals.
The board opposed the shareholder proposal on director resignation guidelines, citing existing robust governance practices.
Shareholder proposals
A shareholder proposal sought to require automatic acceptance of director resignations if not re-elected, aiming to strengthen shareholder voting rights.
The board recommended voting against the proposal, considering it overly prescriptive.
The proposal received 20.9% affirmative votes, failing to pass.
Latest events from Organon
- Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances.OGN
Q2 202631 Jul 2026 - Merger with Sun Pharma USA and related executive compensation were approved by shareholders.OGN
EGM 202623 Jul 2026 - Stockholders to vote on Sun Pharma merger amid litigation and new proxy disclosures.OGN
Proxy filing17 Jul 2026 - Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, board recommends approval.OGN
Proxy filing17 Jun 2026 - Shareholders will soon vote on the Sun Pharma acquisition amid strong performance and cultural focus.OGN
Proxy filing11 Jun 2026 - All proposals passed, with director elections and executive compensation approved by shareholders.OGN
AGM 20269 Jun 2026 - Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, closing expected in 2027.OGN
Proxy filing1 Jun 2026 - Net income rose 68% to $146 million on $1.46 billion revenue, with a pending merger and remediation.OGN
Q1 20264 May 2026 - Organon and Sun Pharma announce a merger with strong employee protections and a pending shareholder vote.OGN
Proxy filing30 Apr 2026